Different domains of the glucagon and glucagon‐like peptide‐1 receptors provide the critical determinants of ligand selectivity
- 1 March 2003
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 138 (5) , 787-794
- https://doi.org/10.1038/sj.bjp.0705120
Abstract
(1) Glucagon and glucagon-like peptide-1 (GLP-1) are homologous peptide hormones with important functions in glucose metabolism. The receptors for glucagon and GLP-1 are homologous family B G-protein coupled receptors. The GLP-1 receptor amino-terminal extracellular domain is a major determinant of glucagon/GLP-1 selectivity of the GLP-1 receptor. However, the divergent residues in glucagon and GLP-1 that determine specificity for the GLP-1 receptor amino-terminal extracellular domain are not known. Less is known about how the glucagon receptor distinguishes between glucagon and GLP-1. (2) We analysed chimeric glucagon/GLP-1 peptides for their ability to bind and activate the glucagon receptor, the GLP-1 receptor and chimeric glucagon/GLP-1 receptors. The chimeric peptide GLP-1(7-20)/glucagon(15-29) was unable to bind and activate the glucagon receptor. Substituting the glucagon receptor core domain with the GLP-1 receptor core domain (chimera A) completely rescued the affinity and potency of GLP-1(7-20)/glucagon(15-29) without compromising the affinity and potency of glucagon. Substituting transmembrane segment 1 (TM1), TM6, TM7, the third extracellular loop and the intracellular carboxy-terminus of chimera A with the corresponding glucagon receptor segments re-established the ability to distinguish GLP-1(7-20)/glucagon(15-29) from glucagon. Corroborant results were obtained with the opposite chimeric peptide glucagon(1-14)/GLP-1(21-37). (3) The results suggest that the glucagon and GLP-1 receptor amino-terminal extracellular domains determine specificity for the divergent residues in the glucagon and GLP-1 carboxy-terminals respectively. The GLP-1 receptor core domain is not a critical determinant of glucagon/GLP-1 selectivity. Conversely, the glucagon receptor core domain contains two or more sub-segments which strongly determine specificity for divergent residues in the glucagon amino-terminus.Keywords
This publication has 54 references indexed in Scilit:
- Mutational analysis of the glucagon receptor: similarities with the vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide (PACAP)/secretin receptors for recognition of the ligand’s third residueBiochemical Journal, 2002
- GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: Selection of NN2211 for clinical developmentDrugs of the Future, 2001
- Domains determining agonist selectivity in chimaeric VIP2 (VPAC2)/PACAP (PAC1) receptorsBritish Journal of Pharmacology, 1999
- The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptorsPeptides, 1996
- Multiple Extracellular Loop Domains Contribute Critical Determinants for Agonist Binding and Activation of the Secretin ReceptorJournal of Biological Chemistry, 1996
- Vasoactive Intestinal Peptide (VIP)1 ReceptorPublished by Elsevier ,1996
- Characterization of Deletion and Truncation Mutants of the Rat Glucagon ReceptorPublished by Elsevier ,1995
- The human glucagon receptor encoding gene: structure, cDNA sequence and chromosomal localizationGene, 1994
- Structural requirements for the occupancy of pituitary adenylate‐cyclase‐activating‐peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB‐OK‐1 cell membranesEuropean Journal of Biochemistry, 1992
- Glucagon antagonistsEuropean Journal of Biochemistry, 1987